Gil Beyen, Erytech Pharma CEO
August 25, 2022 10:51 AM EDTUpdated 11:43 AM
R&D
FDA+

French pen­ny stock will no longer knock on FDA door for ap­proval in a cer­tain type of blood can­cer

Aayushi Pratap

News Reporter

Things are not look­ing up for the French biotech Ery­tech Phar­ma.

The com­pa­ny is knock­ing off its plan to get FDA ap­proval for its drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times